Two monoclonal antibodies against MCF-7 human estrogen receptors were used for immunoperoxidase staining of paraffin sections of human breast cancer tissue. The staining was predominantly located in the nucleus of epithelial cells. Variation in the staining intensity was observed among individual cells. A significant positive correlation between the number of positively stained cells and cytosol estrogen receptor content (fmol of bound estrogen/mg of protein) was observed. The potential and the limitations of the present techniques are discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/33.2.2578501 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cytokines in hematopoietic cell transplantation and related cellular therapies.
Best Pract Res Clin Haematol
December 2024
Division of Hematology/Oncology, Columbia University Irving Medical Center/New York-Presbyterian Hospital, New York, NY, USA; Columbia Center for Translational Immunology, Vagelos College of Physicians and Surgeons, Columbia University, New York City, USA. Electronic address:
Cytokines are pleiotropic molecules involved in hematopoiesis, immune responses, infections, and inflammation. They play critical roles in hematopoietic cell transplantation (HCT) and immune effector cell (IEC) therapies, mediating both therapeutic and adverse effects. Thus, cytokines contribute to the immunopathology of graft-versus-host disease (GVHD), cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS).
View Article and Find Full Text PDFFc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors.
J Immunother Cancer
March 2025
St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King's College London, London, UK
Background: Anti-human epidermal growth factor receptor 2 (HER2) IgG1-based antibody therapies significantly improve cancer prognosis, yet intrinsic or acquired resistance to fragment antigen-binding (Fab)-mediated direct effects commonly occurs. Most resistant tumors retain antigen expression and therefore remain potentially targetable with anti-HER2 therapies that promote immune-mediated responses. Tumor-antigen-specific IgE class antibodies can mediate powerful immune cell-mediated effects against different cancers and have been shown to activate IgE Fc receptor-expressing monocytes.
View Article and Find Full Text PDFThe 1-year survival rate of patients with unresectable hepatocellular carcinoma is less than 50%, which indicates a poor prognosis. Recently, the combination of atezolizumab and bevacizumab has improved the prognosis of patients with advanced hepatocellular carcinoma and has become the first-line treatment for unresectable hepatocellular carcinoma. However, there are few reports on conversion surgery after chemotherapy for unresectable hepatocellular carcinoma.
View Article and Find Full Text PDF[A Case of Successful Hepatic Resection of Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab for Recurrent Liver and Lung Metastases].
Gan To Kagaku Ryoho
February 2025
Dept. of General Surgery, Graduate School of Medicine, Chiba University.
Drug therapy for hepatocellular carcinoma has made remarkable progress in recent years, and surgical resection of tumors that respond well to drug therapy has been performed in some cases. We report a case of hepatocellular carcinoma with hepatopulmonary metastases that was successfully treated with atezolizumab plus bevacizumab and surgically resected. The patient was a 56-year-old man who underwent a posterior segmentectomy and was diagnosed with hepatocellular carcinoma.
View Article and Find Full Text PDF[A Case of Bullous Pemphigoid after Combined Chemotherapy of Durvalumab, Gemcitabine and Cisplatin for Intrahepatic Cholangiocarcinoma].
Gan To Kagaku Ryoho
February 2025
Dept. of Surgery, Kaizuka City Hospital.
The patient is a 66-year-old man. He underwent a total of 9 courses of GCD therapy(gemcitabine+cisplatin+durvalumab)for intrahepatic cholangiocarcinoma with direct invasion of the greater omentum and abdominal wall and surrounding peritoneal dissemination. The tumor had shrunk and was judged to be curative, and laparoscopic hepatic S4a/S5 subsegmentectomy and S6 partial hepatectomy were performed at 8 months after the initial diagnosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!